SPI1 and acute myeloid leukemia: Bašová P. et al. succeeded to induce increased levels of PU.1 in an AML (Acute myeloid leukemia) mouse model by administrating a combination of three therapeutic agents: AZA (5-Azacytidine), CEL (Celastrol), and AM155 (anti-miR-155), which inhibited the growth of myeloid malignant cells and prolonged the survival of mice with AML [86].